<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="spg3a" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">spg3a</book-part-id>
      <title-group>
        <title>Spastic Paraplegia 3A</title>
        <alt-title alt-title-type="alt-title">Synonym: SPG3A</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hedera</surname>
            <given-names>Peter</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Department of Neurology<break/>Vanderbilt University<break/>Nashville, Tennessee</aff>
          <email>peter.hedera@vanderbilt.edu</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>21</day>
          <month>9</month>
          <year>2010</year>
        </date>
        <date date-type="updated">
          <day>11</day>
          <month>12</month>
          <year>2014</year>
        </date>
        <date date-type="revised">
          <day>9</day>
          <month>2</month>
          <year>2012</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="sotos" document-type="chapter">Sotos Syndrome</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="spg4" document-type="chapter">Spastic Paraplegia 4</related-object>
      <abstract id="spg3a.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Spastic paraplegia 3A (SPG3A) is a hereditary spastic paraplegia (HSP) characterized by progressive bilateral and mostly symmetric spasticity and weakness of the legs, diminished vibration sense caused by degeneration of the corticospinal tracts and dorsal columns, and urinary bladder hyperactivity. The average age of onset is four years. More than 80% of reported individuals manifest spastic gait before the end of the first decade of life. Most persons with early-onset SPG3A have a &#x0201c;pure&#x0201d; (&#x0201c;uncomplicated&#x0201d;) HSP; however, complicated HSP with axonal motor neuropathy and/or distal amyotrophy with lower motor neuron involvement (Silver syndrome phenotype) have been observed. The rate of progression in SPG3A is slow, and wheelchair dependency or need for a walking aid (cane, walker, or wheelchair) is relatively rare.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of SPG3A can be established only by molecular genetic testing of <italic toggle="yes">ATL1,</italic> the gene encoding the protein atlastin-1.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Treatment is symptomatic. Medical treatment of spasticity may begin with oral baclofen or tizanidine, followed by chemodenervation with botulinum A or B toxins if oral antispasticity medications are not tolerated. Intrathecal baclofen pump may be considered for those who improve on oral baclofen but have significant systemic adverse effects. Medical therapy should be combined with intensive physical therapy focused on stretching and strengthening exercises. Distal weakness (typically affecting foot dorsiflexion) can be ameliorated by ankle-foot orthoses. Urinary urgency can be treated with anticholinergic antispasmodic drugs.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Muscle tendon contractures, scoliosis, and foot deformities, the most likely secondary complications, may be delayed or minimized with intense and regular physiotherapy for the spasticity.</p>
          <p><italic toggle="yes">Surveillance:</italic> No consensus exists regarding the frequency of clinical follow up visits, but reevaluation once or twice yearly to identify and treat new complications is recommended.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Dantrolene, as it can induce irreversible weakness, adversely affecting mobility.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>SPG3A is almost exclusively inherited in an autosomal dominant manner. More than 95% of individuals diagnosed with SPG3A have an affected parent; however, the proportion of cases caused by a <italic toggle="yes">de novo</italic> pathogenic variant is currently unknown. Each child of an individual with SPG3A has a 50% chance of inheriting the pathogenic variant. Prenatal diagnosis for pregnancies at increased risk is possible if the pathogenic variant has been identified in the family.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="spg3a.Diagnosis">
        <title>Diagnosis</title>
        <sec id="spg3a.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p>Spastic paraplegia 3A (SPG3A) is one of the hereditary spastic paraplegias (HSPs), a group of neurodegenerative disorders characterized by progressive bilateral and mostly symmetric lower extremity weakness and spasticity resulting from axonal degeneration of corticospinal tracts, diminished vibration sense caused by impairment of dorsal columns, and urinary bladder hyperactivity.</p>
          <p>Because of the significant overlap between the age of onset and severity of disease among the various genetic types of HSP (see <related-object link-type="booklink" source-id="gene" document-id="hsp" document-type="chapter">Hereditary Spastic Paraplegia</related-object>), the diagnosis of SPG3A can be established only by molecular testing of <italic toggle="yes">ATL1,</italic> the gene associated with SPG3A.</p>
        </sec>
        <sec id="spg3a.Molecular_Genetic_Testing">
          <title>Molecular Genetic Testing</title>
          <p><bold>Gene.</bold>
<italic toggle="yes">ATL1</italic> (formerly known as <italic toggle="yes">SPG3A</italic>)<italic toggle="yes">,</italic> encoding the protein atlastin-1, is the only gene known to be associated with spastic paraplegia 3A.</p>
          <table-wrap id="spg3a.T.summary_of_molecular_genetic_tes" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Summary of Molecular Genetic Testing Used in Spastic Paraplegia 3A</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_spg3a.T.summary_of_molecular_genetic_tes_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_spg3a.T.summary_of_molecular_genetic_tes_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_spg3a.T.summary_of_molecular_genetic_tes_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with a Pathogenic Variant Detectable by This Method</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_spg3a.T.summary_of_molecular_genetic_tes_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">ATL1</italic>
                  </td>
                  <td headers="hd_h_spg3a.T.summary_of_molecular_genetic_tes_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>2,&#x000a0;3</sup></td>
                  <td headers="hd_h_spg3a.T.summary_of_molecular_genetic_tes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">~100%</td>
                </tr>
                <tr>
                  <td headers="hd_h_spg3a.T.summary_of_molecular_genetic_tes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>4,&#x000a0;5</sup></td>
                  <td headers="hd_h_spg3a.T.summary_of_molecular_genetic_tes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;1%</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="spg3a.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="spg3a" object-id="spg3a.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein. See <xref ref-type="sec" rid="spg3a.Molecular_Genetics">Molecular Genetics </xref>for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="spg3a.TF.1.2">
                <label>2. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="spg3a.TF.1.3">
                <label>3. </label>
                <p>Sequence analysis and scanning of the entire gene for pathogenic variants can have similar variant detection frequencies; however, variant detection rates for scanning may vary considerably between laboratories depending on the specific protocol used.</p>
              </fn>
              <fn id="spg3a.TF.1.4">
                <label>4. </label>
                <p>Testing that identifies exon or whole-gene deletions/duplications not detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA. Included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
              </fn>
              <fn id="spg3a.TF.1.5">
                <label>5. </label>
                <p>Single-exon or multiexon deletions in <italic toggle="yes">ATL1</italic> are rare; only one single-exon deletion has been reported to date [<xref ref-type="bibr" rid="spg3a.REF.sulek.2013.239">Sulek et al 2013</xref>].</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Interpretation of test results.</bold> Failure to detect a pathogenic <italic toggle="yes">ATL1</italic> sequence variant does not absolutely exclude the diagnosis of SPG3A because the frequency of pathogenic variants involving non-coding regions (introns and promoter region) is unknown.</p>
        </sec>
        <sec id="spg3a.Testing_Strategy">
          <title>Testing Strategy</title>
          <p>
            <bold>To confirm/establish the diagnosis in a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Genotype/phenotype correlation in persons with hereditary spastic paraplegia (HSP) has a low sensitivity; the diagnosis of SPG3A can be established only by molecular genetic testing.</p>
            </list-item>
            <list-item>
              <p>The yield of molecular genetic testing of <italic toggle="yes">ATL1</italic> in individuals who represent simplex cases (i.e., a single occurrence in a family) is unknown, but molecular genetic testing should be considered if acquired causes of spastic paraparesis have been ruled out [<xref ref-type="bibr" rid="spg3a.REF.rainier.2006.445">Rainier et al 2006</xref>].</p>
            </list-item>
          </list>
          <p><bold>One genetic testing strategy</bold> is molecular genetic testing of <italic toggle="yes">ATL.</italic></p>
          <list list-type="bullet">
            <list-item>
              <p>Sequence analysis should be performed first.</p>
            </list-item>
            <list-item>
              <p>If no pathogenic variant is found through sequence analysis, deletion/duplication analysis can be considered.</p>
            </list-item>
          </list>
          <p><bold>An alternative genetic testing strategy</bold> is use of a multi-gene panel that includes <italic toggle="yes">ATL1</italic> and other genes of interest (see <xref ref-type="sec" rid="spg3a.Differential_Diagnosis">Differential Diagnosis</xref>). Note: The genes included and the methods used in multi-gene panels vary by laboratory and over time.</p>
          <p>For more information on multi-gene panels click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.MultiGene_Panels" object-type="sec">here</related-object>.</p>
          <p><bold>More comprehensive genomic testing</bold> (when available) including exome sequencing, genome sequencing, and mitochondrial sequencing may be considered if single-gene testing (and/or use of a multi-gene panel) fails to confirm a diagnosis in an individual with features of SPG3A.</p>
          <p>For more information on comprehensive genome sequencing click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.Comprehensive_Genome_Sequencing" object-type="sec">here</related-object>.</p>
        </sec>
      </sec>
      <sec id="spg3a.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="spg3a.Clinical_Description">
          <title>Clinical Description</title>
          <p>Spastic paraplegia 3A (SPG3A) is characterized by clinical findings that tend to be more homogeneous than other forms of AD HSP [<xref ref-type="bibr" rid="spg3a.REF.zhao.2001.326">Zhao et al 2001</xref>, <xref ref-type="bibr" rid="spg3a.REF.d_rr.2004.1867">D&#x000fc;rr et al 2004</xref>, <xref ref-type="bibr" rid="spg3a.REF.hedera.2004.1600">Hedera et al 2004</xref>]. The average age of onset is four years. More than 80% of reported individuals manifest spastic gait before the end of the first decade of life. The rate of progression is slow; wheelchair dependency or need for an assistive walking device is relatively rare.</p>
          <p>Although it has been suggested that SPG3A is a neurodevelopmental rather than a neurodegenerative disorder, recent identification of individuals with adult-onset SPG3A argues strongly against this hypothesis [<xref ref-type="bibr" rid="spg3a.REF.sauter.2004.98">Sauter et al 2004</xref>, <xref ref-type="bibr" rid="spg3a.REF.zhu.2006.1343">Zhu et al 2006</xref>]. Persons with adult onset of SPG3A also tend to experience slower progression of their clinical symptoms.</p>
          <p>Most persons with early-onset SPG3A have a &#x0201c;pure&#x0201d; or uncomplicated&#x0201d; HSP phenotype. However, complex HSP phenotypes with axonal motor neuropathy and/or distal amyotrophy (like that observed in the Silver syndrome phenotype) have also been reported [<xref ref-type="bibr" rid="spg3a.REF.scarano.2005.901">Scarano et al 2005</xref>, <xref ref-type="bibr" rid="spg3a.REF.ivanova.2007.706">Ivanova et al 2007</xref>, <xref ref-type="bibr" rid="spg3a.REF.salameh.2009.57">Salameh et al 2009</xref>].</p>
          <p>Signs seen less frequently in SPG3A than in other HSPs include the following [<xref ref-type="bibr" rid="spg3a.REF.d_rr.2004.1867">D&#x000fc;rr et al 2004</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>Hyperreflexia of the upper extremities</p>
            </list-item>
            <list-item>
              <p>Impairment of vibration sensation at the ankles</p>
            </list-item>
            <list-item>
              <p>Urinary sphincter hyperactivity</p>
            </list-item>
          </list>
          <p>Signs seen more frequently in SPG3A than in other HSPs are pes cavus deformities and scoliosis; however, the presence of these findings may be attributable to the earlier age of onset rather than the specific form of HSP.</p>
        </sec>
        <sec id="spg3a.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>Most persons with pathogenic variants in <italic toggle="yes">ATL1</italic> and early-onset disease have pathogenic missense variants clustered around the GTPase binding domain.</p>
          <p>While some <italic toggle="yes">ATL1</italic> pathogenic variants associated with late-onset HSP are insertional variants in the C-terminus of the gene that result in a premature truncation of the protein, adult-onset disease has also been observed with missense variants in the GTPase binding domain [<xref ref-type="bibr" rid="spg3a.REF.tessa.2002.2002">Tessa et al 2002</xref>, <xref ref-type="bibr" rid="spg3a.REF.sauter.2004.98">Sauter et al 2004</xref>].</p>
        </sec>
        <sec id="spg3a.Penetrance">
          <title>Penetrance</title>
          <p>Overall, penetrance of pathogenic variants is high (~80%-90%) [<xref ref-type="bibr" rid="spg3a.REF.d_rr.2004.1867">D&#x000fc;rr et al 2004</xref>]. In many familial cases, individuals with an <italic toggle="yes">ATL1</italic> pathogenic variant had a normal neurologic examination even at an advanced age, arguing against significant age-dependent penetrance [<xref ref-type="bibr" rid="spg3a.REF.d_rr.2004.1867">D&#x000fc;rr et al 2004</xref>].</p>
          <p>The lowest penetrance, 30%, was reported for the <xref ref-type="table" rid="spg3a.T.selected_atl1_pathogenic_variant">p.Arg415Trp</xref> pathogenic variant [<xref ref-type="bibr" rid="spg3a.REF.d_amico.2004.2138">D&#x02019;Amico et al 2004</xref>].</p>
        </sec>
        <sec id="spg3a.Anticipation">
          <title>Anticipation</title>
          <p>Anticipation with an earlier age at onset and increased severity in successive generations is not a feature of the majority of SPG3A kindreds. However, a bias of ascertainment towards earlier recognition of HSP in younger generations of a family is commonly observed based on awareness of the disease by other family members and treating physicians.</p>
        </sec>
        <sec id="spg3a.Nomenclature">
          <title>Nomenclature</title>
          <p>&#x0201c;Silver syndrome phenotype&#x0201d; refers to the inherited findings of spasticity and axonal motor neuropathy and/or distal amyotrophy [<xref ref-type="bibr" rid="spg3a.REF.silver.1966.69">Silver 1966</xref>]. It is now known that these findings can be seen in a number of hereditary neurologic disorders caused by pathogenic variants in different genes (e.g., SPG3A caused by pathogenic variants in <italic toggle="yes">ATL1</italic> and <related-object link-type="booklink" source-id="gene" document-id="spg17" document-type="chapter"><italic toggle="yes">BSCL2</italic>-related neurologic disorders</related-object> caused by pathogenic variants in <italic toggle="yes">BSCL2</italic>) [<xref ref-type="bibr" rid="spg3a.REF.windpassinger.2004.271">Windpassinger et al 2004</xref>].</p>
        </sec>
        <sec id="spg3a.Prevalence">
          <title>Prevalence</title>
          <p>Estimated prevalence of AD HSP varies from 1.27:100,000 in the survey in Ireland to 12.4:100,000 based on a Norwegian epidemiologic study [<xref ref-type="bibr" rid="spg3a.REF.skre.1974.165">Skre 1974</xref>, <xref ref-type="bibr" rid="spg3a.REF.mcmonagle.2002.43">McMonagle et al 2002</xref>].</p>
          <p><italic toggle="yes">ATL1</italic> pathogenic variants have been confirmed as the most common cause of early-onset HSP, accounting for approximately 30%-50% of all AD HSP with onset before age ten years [<xref ref-type="bibr" rid="spg3a.REF.abel.2004.239">Abel et al 2004</xref>, <xref ref-type="bibr" rid="spg3a.REF.d_rr.2004.1867">D&#x000fc;rr et al 2004</xref>].</p>
          <p>SPG3A accounts for approximately 10%-15% of all AD HSP cases [<xref ref-type="bibr" rid="spg3a.REF.fink.1996.1507">Fink et al 1996</xref>]. In an analysis of a large cohort of patients in whom a <italic toggle="yes">SPAST</italic> (formerly known as <italic toggle="yes">SPG4</italic>) pathogenic variant was not identified, 40% had pathogenic variants in <italic toggle="yes">ATL1</italic> [<xref ref-type="bibr" rid="spg3a.REF.d_rr.2004.1867">D&#x000fc;rr et al 2004</xref>].</p>
        </sec>
      </sec>
      <sec id="spg3a.Genetically_Related_Allelic_Disord">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>SPG3A is allelic with hereditary sensory neuropathy type ID (HSN ID), which is an axonal form of autosomal dominant hereditary motor and sensory neuropathy distinguished by prominent sensory loss that leads to painless injuries. A pathogenic missense variant in <italic toggle="yes">ATL1</italic> was identified in a single family with HSN I; other known HSN I-associated genes were excluded as the cause of polyneuropathy [<xref ref-type="bibr" rid="spg3a.REF.guelly.2011.99">Guelly et al 2011</xref>, <xref ref-type="bibr" rid="spg3a.REF.leonardis.2012.992">Leonardis et al 2012</xref>].</p>
        <p>Clinical presentation with a pure autonomic failure followed by the development of spastic paraplegia has also been reported in one individual with a novel pathogenic splice site variant in exon 2 of <italic toggle="yes">ATL1</italic> [<xref ref-type="bibr" rid="spg3a.REF.shin.2014.141">Shin et al 2014</xref>]. Whether this represents an allelic condition or an atypical presentation of SPG3A remains to be elucidated.</p>
      </sec>
      <sec id="spg3a.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>HSP is a progressive condition with a gradual worsening of spasticity and weakness of the lower extremities. Overall, the age of onset, disease severity, and rate of progression differ among different types of AD HSP; there is also considerable variability within the same genetic forms of HSP.</p>
        <p>For a general discussion of the differential diagnosis of spastic paraplegia/paraparesis syndrome, see <related-object link-type="booklink" source-id="gene" document-id="hsp" document-type="chapter">Hereditary Spastic Paraplegia Overview</related-object>.</p>
        <p>While the association of infantile or early (age &#x0003c;10 years) onset and pathogenic variants in <italic toggle="yes">ATL1</italic> has been confirmed by many studies, this genotype-phenotype correlation is not sufficient for the specific diagnosis of SPG3A on clinical grounds alone as an early age of onset can be seen in other types of AD HSP. Overall, a low specificity of genotype/phenotype correlations in AD HSP requires the molecular diagnosis of a specific type of HSP.</p>
        <p>SPG3A needs to be differentiated from other forms of AD HSP, such as <related-object link-type="booklink" source-id="gene" document-id="spg17" document-type="chapter"><italic toggle="yes">BSCL2</italic>-related neurologic disorders</related-object>, in which the Silver syndrome phenotype can be observed. [<xref ref-type="bibr" rid="spg3a.REF.salameh.2009.57">Salameh et al 2009</xref>].</p>
        <p>SPG3A needs to be differentiated from other forms of AD HSP with possible early age of onset.</p>
        <p>Additional considerations for SPG3A include a diplegic form of cerebral palsy (CP), as the majority of such patients tend to have very early onset of symptoms and a slow progression, which may suggest a static clinical course [<xref ref-type="bibr" rid="spg3a.REF.rainier.2006.445">Rainier et al 2006</xref>]. The presence of a positive family history with an affected parent typically does not present any diagnostic dilemmas. However, incomplete penetrance or a <italic toggle="yes">de novo</italic> pathogenic variant may lead to the diagnosis of diplegia caused by periventricular leukomalacia or perinatal hypoxic-ischemic injury. Normal pre- and perinatal history and unremarkable neuroimaging should prompt consideration of HSP, including SPG3A.</p>
        <p><related-object link-type="booklink" source-id="gene" document-id="spg4" document-type="chapter">SPG4</related-object>, caused by pathogenic variants in <italic toggle="yes">SPAST</italic> (encoding spastin) is the most common type of AD HSP; it may occasionally present in infancy, although it tends to have a more progressive course [<xref ref-type="bibr" rid="spg3a.REF.blair.2007.382">Blair et al 2007</xref>].</p>
        <p>SPG6 (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/600636">600363</ext-link>), caused by pathogenic variants in <italic toggle="yes">NIPA1</italic> (encoding magnesium transporter NIPA1), may occasionally also manifest in infancy [<xref ref-type="bibr" rid="spg3a.REF.bienwillner.2006.974">Bien-Willner et al 2006</xref>]. This is probably the most aggressive form of AD HSP, leading to wheelchair dependency in a relatively short period of time.</p>
        <p>SPG10 (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/604187">604187</ext-link>), caused by pathogenic variants in <italic toggle="yes">KIF5A</italic> (encoding kinesin 5A), is probably the second most common cause of early-onset AD HSP. Axonal motor neuropathy is common [<xref ref-type="bibr" rid="spg3a.REF.reid.2002.1189">Reid et al 2002</xref>].</p>
        <p>SPG42 (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/612539">612539</ext-link>), caused by pathogenic variants in <italic toggle="yes">SLC33A1</italic> (encoding acetyl-coenzyme A transporter 1), may also start in the first decade of life and has a mild, minimally progressive clinical course. Pes cavus and distal amyotrophy are common [<xref ref-type="bibr" rid="spg3a.REF.lin.2008.752">Lin et al 2008</xref>]. This form of HSP has been reported in a single family.</p>
      </sec>
      <sec id="spg3a.Management">
        <title>Management</title>
        <sec id="spg3a.Evaluations_Following_Initial_Diag">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with spastic paraplegia 3A (SPG3A), the following evaluations may be indicated:</p>
          <list list-type="bullet">
            <list-item>
              <p>Orthopedic evaluation in persons with early onset of SPG3A who have developed musculoskeletal complications including scoliosis or foot deformities</p>
            </list-item>
            <list-item>
              <p>Physical and occupational therapy evaluation in children with early onset of disease</p>
            </list-item>
            <list-item>
              <p>Urologic evaluation in persons with prominent urinary bladder hyperactivity</p>
            </list-item>
            <list-item>
              <p>Electromyography and nerve conduction studies in persons with associated axonal neuropathy or neurogenic pain in the lower extremities caused by possible lumbo-sacral radiculopathy secondary to lumbar hyperlordosis and degenerative vertebral changes</p>
            </list-item>
            <list-item>
              <p>Clinical genetics consultation</p>
            </list-item>
          </list>
        </sec>
        <sec id="spg3a.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Therapy for spasticity, distal weakness, and urinary bladder dysfunction, the primary manifestations of SPG3A, is symptomatic.</p>
          <p><bold>Spasticity</bold> can be treated with:</p>
          <list list-type="bullet">
            <list-item>
              <p>Oral baclofen or tizanidine</p>
            </list-item>
            <list-item>
              <p>Chemodenervation with botulinum A or B toxins; may be tried in those who do not tolerate oral antispasticity medications</p>
            </list-item>
            <list-item>
              <p>Intrathecal baclofen pump; a good alternative for patients who improve on oral baclofen but cannot tolerate a therapeutic dose because of systemic adverse effects</p>
            </list-item>
          </list>
          <p>Each of the above therapies should be combined with intensive physical therapy focused on stretching and strengthening exercises.</p>
          <p>The role of surgical therapy for spasticity (including hamstring and heel cord lengthening and release of the adductor longus) remains unknown, but such treatment should be considered if contractures appear. See also <xref ref-type="sec" rid="spg3a.Prevention_of_Secondary_Complicati">Prevention of Secondary Complications</xref>.</p>
          <p><bold>Distal weakness</bold>, typically affecting foot dorsiflexion, can be ameliorated by ankle-foot orthoses; referral to orthotic services may be helpful.</p>
          <p><bold>Urinary urgency</bold> can be treated with anticholinergic antispasmodic drugs.</p>
        </sec>
        <sec id="spg3a.Prevention_of_Secondary_Complicati">
          <title>Prevention of Secondary Complications</title>
          <p>Musculoskeletal abnormalities including muscle tendon contractures, scoliosis, and foot deformities are the secondary complications most likely to occur, resulting from long-standing spasticity and weakness. Intense and regular therapy for spasticity, including physiotherapy, can delay and minimize the appearance of these complications. The higher incidence of orthopedic problems in patients with SPG3A may be related to early age of onset and these patients should be followed by an orthopedist if problems are present.</p>
          <p>Urinary bladder incontinence can be a secondary complication of a neurogenic bladder and urologic care may be needed.</p>
          <p>Patients with advanced disease may experience falls with a risk of traumatic injury. A walking aid (cane, walker, or wheelchair) may need to be considered in patients experiencing falls.</p>
        </sec>
        <sec id="spg3a.Surveillance">
          <title>Surveillance</title>
          <p>There is no consensus regarding the frequency of clinical follow-up visits, but every person with HSP should be reevaluated once or twice a year to identify new complications early and to initiate aggressive therapy as indicated.</p>
        </sec>
        <sec id="spg3a.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Dantrolene should be avoided in persons who are ambulatory as it may induce irreversible weakness, which can adversely interfere with overall mobility.</p>
        </sec>
        <sec id="spg3a.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="spg3a.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="spg3a.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>The use of regional anesthesia, such as spinal or epidural anesthesia, during delivery in affected women with spinal cord involvement has traditionally been avoided due to the theoretic risk of exacerbating the degree of weakness and spasticity. However, several cases of successful regional anesthesia in affected individuals with hereditary spastic paraplegia have been reported [<xref ref-type="bibr" rid="spg3a.REF.thomas.2006.254">Thomas et al 2006</xref>].</p>
        </sec>
        <sec id="spg3a.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ClinicalTrials.gov">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="spg3a.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="spg3a.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Spastic paraplegia 3A (SPG3A) is typically inherited in an autosomal dominant manner.</p>
          <p>Recently, a family with SPG3A with presumed autosomal recessive inheritance was reported by <xref ref-type="bibr" rid="spg3a.REF.khan.2014.1180">Khan et al [2014]</xref>. Such inheritance is extremely rare and as yet unconfirmed.</p>
        </sec>
        <sec id="spg3a.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Most individuals (&#x0003e;95%) diagnosed with spastic paraplegia 3A have an affected parent.</p>
            </list-item>
            <list-item>
              <p>A proband with SPG 3A may have the disorder as the result of a <italic toggle="yes">de novo</italic> pathogenic variant. The proportion of cases caused by <italic toggle="yes">de novo</italic> pathogenic variants is currently unknown.</p>
            </list-item>
            <list-item>
              <p>If the <italic toggle="yes">ATL1</italic> pathogenic variant found in the proband cannot be detected in leukocyte DNA of either parent, two possible explanations are germline mosaicism in a parent or a <italic toggle="yes">de novo</italic> pathogenic variant in the proband. Although no instances of germline mosaicism have been reported, it remains a possibility.</p>
            </list-item>
            <list-item>
              <p>Recommendations for the evaluation of parents of a proband with an apparent <italic toggle="yes">de novo</italic> pathogenic variant include a comprehensive neurologic examination.</p>
            </list-item>
            <list-item>
              <p>The family history of some individuals diagnosed with SPG3A may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset of the disease in the affected parent. Therefore, an apparently negative family history cannot be confirmed unless appropriate molecular genetic testing has been performed on the parents of the proband.</p>
            </list-item>
          </list>
          <p>Note: If the parent is the individual in whom the pathogenic variant first occurred, s/he may have somatic mosaicism for the pathogenic variant and may be mildly/minimally affected.</p>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the sibs of the proband depends on the genetic status of the proband&#x02019;s parents.</p>
            </list-item>
            <list-item>
              <p>If a parent of the proband is affected and/or has an <italic toggle="yes">ATL1</italic> pathogenic variant, the risk to the sibs of inheriting the variant is 50%.</p>
            </list-item>
            <list-item>
              <p>When the parents are clinically unaffected, the risk to the sibs of a proband appears to be low (&#x0003c; 5%).</p>
            </list-item>
            <list-item>
              <p>The sibs of a proband with clinically unaffected parents are still at increased risk for spastic paraplegia 3A because of the possibility of reduced penetrance in a parent.</p>
            </list-item>
            <list-item>
              <p>If the <italic toggle="yes">ATL1</italic> pathogenic variant found in the proband cannot be detected in the leukocyte DNA of either parent, the risk to sibs is low, but greater than that of the general population because of the possibility of germline mosaicism.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Each child of an individual with spastic paraplegia 3A has a 50% chance of inheriting the <italic toggle="yes">ATL1</italic> pathogenic variant.</p>
          <p>
            <bold>Other family members</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to other family members depends on the status of the proband's parents.</p>
            </list-item>
            <list-item>
              <p>If a parent is affected or has an <italic toggle="yes">ATL1</italic> pathogenic variant, his or her family members may be at risk.</p>
            </list-item>
          </list>
        </sec>
        <sec id="spg3a.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p><bold>Testing of at-risk asymptomatic adult relatives</bold> of individuals with SPG3A is possible after molecular genetic testing has identified the specific pathogenic variant in the family. Such testing should be performed in the context of formal genetic counseling and is not useful in predicting age of onset, severity, type of symptoms, or rate of progression in asymptomatic individuals. Testing of asymptomatic at-risk individuals with nonspecific or equivocal symptoms is predictive testing, not diagnostic testing.</p>
          <p><bold>Testing of asymptomatic individuals younger than age 18 years</bold> who are at risk for adult-onset disorders for which no treatment exists is not considered appropriate, primarily because it negates the autonomy of the child with no compelling benefit. Further, concern exists regarding the potential unhealthy adverse effects that such information may have on family dynamics, the risk of discrimination and stigmatization in the future, and the anxiety that such information may cause.</p>
          <p>Testing is appropriate to consider in symptomatic individuals in a family with an established diagnosis of SPG3A regardless of age.</p>
          <p>See also the National Society of Genetic Counselors <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nsgc.org/p/bl/et/blogaid=860">position statement</ext-link> on genetic testing of minors for adult-onset conditions and the American Academy of Pediatrics and American College of Medical Genetics and Genomics <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf">policy statement</ext-link>: ethical and policy issues in genetic testing and screening of children.</p>
          <p><bold>Considerations in families with an apparent <italic toggle="yes">de novo</italic> pathogenic variant.</bold> When neither parent of a proband with SPG3A has the <italic toggle="yes">ATL1</italic> pathogenic variant, the <italic toggle="yes">ATL1</italic> variant is likely <italic toggle="yes">de novo</italic>. However, possible non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="spg3a.Prenatal_Testing_and_Preimplantati">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">ATL1</italic> pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for SPGA are possible.</p>
          <p>Requests for prenatal testing for conditions which (like SPGA) do not affect intellect or shorten life expectancy are not common. Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although decisions about prenatal testing are the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="spg3a.Resources">
        <title>Resources</title>
      </sec>
      <sec id="spg3a.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">ATL1</italic> is 73 kb in length and spans from nucleotide position 51,026,743 to 51,099,782. Transcript variants encoding two different isoforms with 13 or 14 transcribed exons have been found for this gene. Complementary DNA length varies from 2,74 bp to 2,812 bp for different variants. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="spg3a" object-id="spg3a.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Benign variants.</bold> Both synonymous and nonsynonymous single polymorphisms (benign variants) have been identified (see <xref ref-type="table" rid="spg3a.T.selected_atl1_benign_variants">Table 2</xref>).</p>
        <table-wrap id="spg3a.T.selected_atl1_benign_variants" orientation="portrait" position="anchor">
          <label>Table 2. </label>
          <caption>
            <p>Selected <italic toggle="yes">ATL1</italic> Benign Variants</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                <th id="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference SNP Number</th>
                <th id="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                <th id="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.84A&#x0003e;G</td>
                <td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=35014209">rs35014209</ext-link>
                </td>
                <td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">NA&#x000a0;<sup>1</sup></td>
                <td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_4" rowspan="6" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/213972601">NG_009028.1</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/189181739">NM_015915.4</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_056999.2">NP_056999.2</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/115502838">Q5R4P1.2</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.129C&#x0003e;G</td>
                <td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=17850684">rs17850684</ext-link>
                </td>
                <td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Asp43Glu</td>
              </tr>
              <tr>
                <td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.351G&#x0003e;A</td>
                <td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/sites/snp">rs1060197</ext-link>
                </td>
                <td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
              </tr>
              <tr>
                <td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.578T&#x0003e;G</td>
                <td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=17850683">rs17850683</ext-link>
                </td>
                <td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Phe193Cys</td>
              </tr>
              <tr>
                <td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.621G&#x0003e;A</td>
                <td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=35629585">rs35629585</ext-link>
                </td>
                <td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
              </tr>
              <tr>
                <td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1222A&#x0003e;G</td>
                <td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=28939094">rs28939094</ext-link>
                </td>
                <td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Met408Val</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the author. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
            <fn id="spg3a.TF.2.1">
              <label>1. </label>
              <p>Not applicable</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Pathogenic variants.</bold> Most pathogenic variants in <italic toggle="yes">ATL1</italic> are unique and no obvious hot spots for recurrent variants have been identified [<xref ref-type="bibr" rid="spg3a.REF.d_rr.2004.1867">D&#x000fc;rr et al 2004</xref>]. One genomic deletion of exon 4 has been reported [<xref ref-type="bibr" rid="spg3a.REF.sulek.2013.239">Sulek et al 2013</xref>].</p>
        <table-wrap id="spg3a.T.selected_atl1_pathogenic_variant" orientation="portrait" position="anchor">
          <label>Table 3. </label>
          <caption>
            <p>Selected <italic toggle="yes">ATL1</italic> Pathogenic Variants</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_spg3a.T.selected_atl1_pathogenic_variant_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                <th id="hd_h_spg3a.T.selected_atl1_pathogenic_variant_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                <th id="hd_h_spg3a.T.selected_atl1_pathogenic_variant_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_spg3a.T.selected_atl1_pathogenic_variant_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1243C&#x0003e;T</td>
                <td headers="hd_h_spg3a.T.selected_atl1_pathogenic_variant_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg415Trp&#x000a0;<sup>2</sup></td>
                <td headers="hd_h_spg3a.T.selected_atl1_pathogenic_variant_1_1_1_3" rowspan="6" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/189181739">NM_015915.3</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_056999.2">NP_056999.2</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_spg3a.T.selected_atl1_pathogenic_variant_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.467C&#x0003e;T<break/>(635C&#x0003e;T)</td>
                <td headers="hd_h_spg3a.T.selected_atl1_pathogenic_variant_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.The156Ile</td>
              </tr>
              <tr>
                <td headers="hd_h_spg3a.T.selected_atl1_pathogenic_variant_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.715C&#x0003e;T<break/>(884C&#x0003e;T)</td>
                <td headers="hd_h_spg3a.T.selected_atl1_pathogenic_variant_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg239Cys</td>
              </tr>
              <tr>
                <td headers="hd_h_spg3a.T.selected_atl1_pathogenic_variant_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.773A&#x0003e;G<break/>(942A&#x0003e;C)</td>
                <td headers="hd_h_spg3a.T.selected_atl1_pathogenic_variant_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.His258Arg</td>
              </tr>
              <tr>
                <td headers="hd_h_spg3a.T.selected_atl1_pathogenic_variant_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.479T&#x0003e;G<break/>(638T&#x0003e;C)</td>
                <td headers="hd_h_spg3a.T.selected_atl1_pathogenic_variant_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Leu157Trp</td>
              </tr>
              <tr>
                <td headers="hd_h_spg3a.T.selected_atl1_pathogenic_variant_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1270dupA<break/>(1688insA)</td>
                <td headers="hd_h_spg3a.T.selected_atl1_pathogenic_variant_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ile424AsnfsTer16<break/>(522Stop)</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the author. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
            <fn id="spg3a.TF.3.1">
              <label>1. </label>
              <p>Variant designation that does not conform to current naming conventions</p>
            </fn>
            <fn id="spg3a.TF.3.2">
              <label>2. </label>
              <p>Low-penetrance allele (see <xref ref-type="sec" rid="spg3a.Penetrance">Penetrance</xref>)</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold>
<italic toggle="yes">ATL1</italic> encodes a 558-amino acid protein named atlastin-1 belonging to the subclass of GTPases called dynamins. Dynamins play a role in vesicle transport, especially in the process of recycling of the vesicles. The protein has two transmembrane domains and also contains the GTP binding domain with a catalytic activity [<xref ref-type="bibr" rid="spg3a.REF.zhu.2003.49063">Zhu et al 2003</xref>]. Atlastin-1 is predominantly expressed in the pyramidal neurons giving the origin to the pyramidal tracts, which undergo axonal degeneration in patients with HSP. It localizes predominantly to the endoplasmatic reticulum (ER) and Golgi complex but is also found in other subcellular compartments, including the axonal growth cones [<xref ref-type="bibr" rid="spg3a.REF.zhu.2003.49063">Zhu et al 2003</xref>, <xref ref-type="bibr" rid="spg3a.REF.zhu.2006.1343">Zhu et al 2006</xref>]. Atlastin-1 plays an important role in the formation of the tubular ER network, where it may coordinate the interaction between microtubules and the tubular ER network [<xref ref-type="bibr" rid="spg3a.REF.hu.2009.549">Hu et al 2009</xref>, <xref ref-type="bibr" rid="spg3a.REF.park.2010.1097">Park et al 2010</xref>]. Atlastin-1 also interacts with spastin, which causes the most common form of AD HSP and is known to function as a microtubule-severing protein [<xref ref-type="bibr" rid="spg3a.REF.sanderson.2006.307">Sanderson et al 2006</xref>].</p>
        <p><bold>Abnormal gene product.</bold> Most disease-causing missense variants in <italic toggle="yes">ATL1</italic> are clustered around the GTPase domain, resulting in reduction of catalytic activity. However, it is still not clear whether SPG3A results from a loss of atlastin-1 function: a dominant-negative effect of mutated protein forms on a wild type of atlastin-1 has also been suggested. Atlastin-1 forms tetrameric complexes and heterocomplexes of wild type and mutated atlastin-1 molecules may inactivate the normal function of wild type atlastin-1, consistent with a dominant-negative effect [<xref ref-type="bibr" rid="spg3a.REF.zhu.2003.49063">Zhu et al 2003</xref>]. Expression of pathogenic variants of atlastin-1 results in abnormal connectivity of ER complex and these ER-shaping defects may represent a novel neuropathogenic mechanism [<xref ref-type="bibr" rid="spg3a.REF.hu.2009.549">Hu et al 2009</xref>]. Additionally, atlastin-1 appears to be enriched in neuronal growth cones, and knockdown of atlastin-1 expression was found to impair axonal elongation [<xref ref-type="bibr" rid="spg3a.REF.zhu.2006.1343">Zhu et al 2006</xref>].</p>
      </sec>
      <sec id="spg3a.References">
        <title>References</title>
        <sec id="spg3a.Published_GuidelinesConsensus_Stat">
          <title>Published Guidelines/Consensus Statements</title>
          <ref-list id="spg3a.Published_GuidelinesConsensus_Stat.reflist0">
            <ref id="spg3a.REF1">
              <mixed-citation publication-type="web">Committee on Bioethics, Committee on Genetics, and American College of Medical Genetics and Genomics Social, Ethical, Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf">online</ext-link>. 2013. Accessed 4-25-17.</mixed-citation>
            </ref>
            <ref id="spg3a.REF2">
              <mixed-citation publication-type="web">National Society of Genetic Counselors. Position statement on genetic testing of minors for adult-onset disorders. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nsgc.org/p/bl/et/blogaid=860">online</ext-link>. 2017. Accessed 4-25-17.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="spg3a.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="spg3a.Literature_Cited.reflist0">
            <ref id="spg3a.REF.abel.2004.239">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Abel</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fonknechten</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hofer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D&#x000fc;rr</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cruaud</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voit</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weissenbach</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brice</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klimpe</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Auburger</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hazan</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Early onset autosomal dominant spastic paraplegia caused by novel mutations in SPG3A.</article-title>
                <source>Neurogenetics</source>
                <volume>5</volume>
                <fpage>239</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">15517445</pub-id>
              </element-citation>
            </ref>
            <ref id="spg3a.REF.bienwillner.2006.974">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bien-Willner</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sambuughin</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holley</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bodensteiner</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sivakumar</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Childhood-onset spastic paraplegia with NIPA1 gene mutation.</article-title>
                <source>J Child Neurol</source>
                <volume>21</volume>
                <fpage>974</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">17092466</pub-id>
              </element-citation>
            </ref>
            <ref id="spg3a.REF.blair.2007.382">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Blair</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riddle</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wells</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Breviu</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hedera</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Infantile onset of hereditary spastic paraplegia poorly predicts the genotype.</article-title>
                <source>Pediatr Neurol</source>
                <volume>36</volume>
                <fpage>382</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">17560499</pub-id>
              </element-citation>
            </ref>
            <ref id="spg3a.REF.d_amico.2004.2138">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>D&#x02019;Amico</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tessa</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sabino</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santorelli</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Servidei</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Incomplete penetrance in an SPG3A-linked family with a new mutation in the atlastin gene.</article-title>
                <source>Neurology</source>
                <volume>62</volume>
                <fpage>2138</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15184642</pub-id>
              </element-citation>
            </ref>
            <ref id="spg3a.REF.d_rr.2004.1867">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>D&#x000fc;rr</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camuzat</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Colin</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tallaksen</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hannequin</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coutinho</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fontaine</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gil</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rousselle</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruberg</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stevanin</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brice</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Atlastin1 mutations are frequent in young-onset autosomal dominant spastic paraplegia.</article-title>
                <source>Arch Neurol</source>
                <volume>61</volume>
                <fpage>1867</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">15596607</pub-id>
              </element-citation>
            </ref>
            <ref id="spg3a.REF.fink.1996.1507">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fink</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heiman-Patterson</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bird</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cambi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dub&#x000e9;</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Figlewicz</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haines</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hentati</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pericak-Vance</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raskind</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouleau</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Siddique</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>1996</year>
                <article-title>Hereditary spastic paraplegia: advances in genetic research.</article-title>
                <source>Neurology</source>
                <volume>46</volume>
                <fpage>1507</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">8649538</pub-id>
              </element-citation>
            </ref>
            <ref id="spg3a.REF.guelly.2011.99">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Guelly</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhu</surname>
                    <given-names>PP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leonardis</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Papi&#x00107;</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zidar</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schabh&#x000fc;ttl</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strohmaier</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weis</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strom</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baets</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willems</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Jonghe</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reilly</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fr&#x000f6;hlich</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hatz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trajanoski</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pieber</surname>
                    <given-names>TR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janecke</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blackstone</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Auer-Grumbach</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Targeted high-throughput sequencing identifies mutations in atlastin-1 as a cause of hereditary sensory neuropathy type I.</article-title>
                <source>Am J Hum Genet</source>
                <volume>88</volume>
                <fpage>99</fpage>
                <lpage>105</lpage>
                <pub-id pub-id-type="pmid">21194679</pub-id>
              </element-citation>
            </ref>
            <ref id="spg3a.REF.hedera.2004.1600">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hedera</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fenichel</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blair</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haines</surname>
                    <given-names>JL</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Novel mutation in the SPG3A gene in an African American family with an early onset of hereditary spastic paraplegia.</article-title>
                <source>Arch Neurol</source>
                <volume>61</volume>
                <fpage>1600</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">15477516</pub-id>
              </element-citation>
            </ref>
            <ref id="spg3a.REF.hu.2009.549">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hu</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shibata</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhu</surname>
                    <given-names>PP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voss</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rismanchi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prinz</surname>
                    <given-names>WA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rapoport</surname>
                    <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blackstone</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>A class of dynamin-like GTPases involved in the generation of the tubular ER network.</article-title>
                <source>Cell</source>
                <volume>138</volume>
                <fpage>549</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">19665976</pub-id>
              </element-citation>
            </ref>
            <ref id="spg3a.REF.ivanova.2007.706">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ivanova</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Claeys</surname>
                    <given-names>KG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deconinck</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Litvinenko</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jordanova</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Auer-Grumbach</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haberlova</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>L&#x000f6;fgren</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smeyers</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nelis</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mercelis</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plecko</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Priller</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Z&#x000e1;mecn&#x000ed;k</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ceulemans</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Erichsen</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bj&#x000f6;rck</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nicholson</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sereda</surname>
                    <given-names>MW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seeman</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kremensky</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitev</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Jonghe</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Hereditary spastic paraplegia 3A associated with axonal neuropathy.</article-title>
                <source>Arch Neurol</source>
                <volume>64</volume>
                <fpage>706</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">17502470</pub-id>
              </element-citation>
            </ref>
            <ref id="spg3a.REF.khan.2014.1180">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Khan</surname>
                    <given-names>TN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klar</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tariq</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anjum Baig</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malik</surname>
                    <given-names>NA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yousaf</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baig</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dahl</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>Evidence for autosomal recessive inheritance in SPG3A caused by homozygosity for a novel ATL1 missense mutation.</article-title>
                <source>Eur J Hum Genet</source>
                <volume>22</volume>
                <fpage>1180</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">24473461</pub-id>
              </element-citation>
            </ref>
            <ref id="spg3a.REF.leonardis.2012.992">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Leonardis</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Auer-Grumbach</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Papi&#x00107;</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zidar</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>The N355K atlastin 1 mutation is associated with hereditary sensory neuropathy and pyramidal tract features.</article-title>
                <source>Eur J Neurol</source>
                <volume>19</volume>
                <fpage>992</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">22340599</pub-id>
              </element-citation>
            </ref>
            <ref id="spg3a.REF.lin.2008.752">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mao</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Qiu</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hu</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Song</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gao</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yan</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shao</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gong</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>A missense mutation in SLC33A1, which encodes the acetyl-CoA transporter, causes autosomal-dominant spastic paraplegia (SPG42).</article-title>
                <source>Am J Hum Genet</source>
                <volume>83</volume>
                <fpage>752</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">19061983</pub-id>
              </element-citation>
            </ref>
            <ref id="spg3a.REF.mcmonagle.2002.43">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McMonagle</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Webb</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hutchinson</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>The prevalence of "pure" autosomal dominant hereditary spastic paraparesis in the island of Ireland.</article-title>
                <source>J Neurol Neurosurg Psychiatry</source>
                <volume>72</volume>
                <fpage>43</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">11784824</pub-id>
              </element-citation>
            </ref>
            <ref id="spg3a.REF.park.2010.1097">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Park</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhu</surname>
                    <given-names>PP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parker</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blackstone</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Hereditary spastic paraplegia proteins REEP1, spastin, and atlastin-1 coordinate microtubule interactions with the tubular ER network.</article-title>
                <source>J Clin Invest</source>
                <volume>120</volume>
                <fpage>1097</fpage>
                <lpage>110</lpage>
                <pub-id pub-id-type="pmid">20200447</pub-id>
              </element-citation>
            </ref>
            <ref id="spg3a.REF.rainier.2006.445">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rainier</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sher</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reish</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fink</surname>
                    <given-names>JK</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>De novo occurrence of novel SPG3A/atlastin mutation presenting as cerebral palsy.</article-title>
                <source>Arch Neurol</source>
                <volume>63</volume>
                <fpage>445</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16533974</pub-id>
              </element-citation>
            </ref>
            <ref id="spg3a.REF.reid.2002.1189">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Reid</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kloos</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ashley-Koch</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bevan</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Svenson</surname>
                    <given-names>IK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graham</surname>
                    <given-names>FL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gaskell</surname>
                    <given-names>PC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dearlove</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pericak-Vance</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rubinsztein</surname>
                    <given-names>DC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marchuk</surname>
                    <given-names>DA</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10).</article-title>
                <source>Am J Hum Genet</source>
                <volume>71</volume>
                <fpage>1189</fpage>
                <lpage>94</lpage>
                <pub-id pub-id-type="pmid">12355402</pub-id>
              </element-citation>
            </ref>
            <ref id="spg3a.REF.salameh.2009.57">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Salameh</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shenoy</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>David</surname>
                    <given-names>WS</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Novel SPG3A and SPG4 mutations in two patients with Silver syndrome.</article-title>
                <source>J Clin Neuromuscul Dis</source>
                <volume>11</volume>
                <fpage>57</fpage>
                <lpage>59</lpage>
                <pub-id pub-id-type="pmid">19730024</pub-id>
              </element-citation>
            </ref>
            <ref id="spg3a.REF.sanderson.2006.307">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sanderson</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Connell</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edwards</surname>
                    <given-names>TL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bright</surname>
                    <given-names>NA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duley</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thompson</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luzio</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reid</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>Spastin and atlastin, two proteins mutated in autosomal-dominant hereditary spastic paraplegia, are binding partners.</article-title>
                <source>Hum Mol Genet.</source>
                <year>2006</year>
                <volume>15</volume>
                <fpage>307</fpage>
                <lpage>18</lpage>
                <pub-id pub-id-type="pmid">16339213</pub-id>
              </element-citation>
            </ref>
            <ref id="spg3a.REF.sauter.2004.98">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sauter</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Engel</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neumann</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kunze</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neesen</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Novel mutations in the Atlastin gene (SPG3A) in families with autosomal dominant hereditary spastic paraplegia and evidence for late onset forms of HSP linked to the SPG3A locus.</article-title>
                <source>Hum Mutat</source>
                <volume>23</volume>
                <fpage>98</fpage>
                <pub-id pub-id-type="pmid">14695538</pub-id>
              </element-citation>
            </ref>
            <ref id="spg3a.REF.scarano.2005.901">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Scarano</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mancini</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Criscuolo</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Michele</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rinaldi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tucci</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tessa</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santorelli</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perretti</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santoro</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filla</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>The R495W mutation in SPG3A causes spastic paraplegia associated with axonal neuropathy.</article-title>
                <source>J Neurol</source>
                <volume>252</volume>
                <fpage>901</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">15742100</pub-id>
              </element-citation>
            </ref>
            <ref id="spg3a.REF.shin.2014.141">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shin</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jung</surname>
                    <given-names>KH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>ST</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moon</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seong</surname>
                    <given-names>MW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Park</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chu</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>Novel mutation in the ATL1 with autosomal dominant hereditary spastic paraplegia presented as dysautonomia.</article-title>
                <source>Auton Neurosci</source>
                <volume>185</volume>
                <fpage>141</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">24969372</pub-id>
              </element-citation>
            </ref>
            <ref id="spg3a.REF.silver.1966.69">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Silver</surname>
                    <given-names>JR</given-names>
                  </name>
                </person-group>
                <year>1966</year>
                <article-title>Familial spastic paraplegia with amyotrophy of the hands.</article-title>
                <source>Ann Hum Genet.</source>
                <volume>30</volume>
                <fpage>69</fpage>
                <lpage>75</lpage>
                <pub-id pub-id-type="pmid">5964029</pub-id>
              </element-citation>
            </ref>
            <ref id="spg3a.REF.skre.1974.165">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Skre</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>1974</year>
                <article-title>Hereditary spastic paraplegia in Western Norway.</article-title>
                <source>Clin Genet</source>
                <volume>6</volume>
                <fpage>165</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">4426134</pub-id>
              </element-citation>
            </ref>
            <ref id="spg3a.REF.sulek.2013.239">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sulek</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elert</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rajkiewicz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zdzienicka</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stepniak</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krysa</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zaremba</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Screening for the hereditary spastic paraplaegias SPG4 and SPG3A with the multiplex ligation-dependent probe amplification technique in a large population of affected individuals.</article-title>
                <source>Neurol Sci.</source>
                <volume>34</volume>
                <fpage>239</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">22203332</pub-id>
              </element-citation>
            </ref>
            <ref id="spg3a.REF.tessa.2002.2002">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tessa</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casali</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Damiano</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruno</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fortini</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patrono</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cricchi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valoppi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nappi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amabile</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santorelli</surname>
                    <given-names>FM</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>SPG3A: An additional family carrying a new atlastin mutation.</article-title>
                <source>Neurology</source>
                <volume>59</volume>
                <fpage>2002</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">12499504</pub-id>
              </element-citation>
            </ref>
            <ref id="spg3a.REF.thomas.2006.254">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scrutton</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Spinal anaesthesia in a patient with hereditary spastic paraplegia: case report and literature review.</article-title>
                <source>Int J Obstet Anesth</source>
                <volume>15</volume>
                <fpage>254</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">16798455</pub-id>
              </element-citation>
            </ref>
            <ref id="spg3a.REF.windpassinger.2004.271">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Windpassinger</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Auer-Grumbach</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Irobi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patel</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petek</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>H&#x000f6;rl</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malli</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reed</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dierick</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verpoorten</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Warner</surname>
                    <given-names>TT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Proukakis</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van den Bergh</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verellen</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Maldergem</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merlini</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Jonghe</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Timmerman</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crosby</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wagner</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Heterozygous missense mutations in BSCL2 are associated with distal hereditary motor neuropathy and Silver syndrome.</article-title>
                <source>Nat Genet</source>
                <volume>36</volume>
                <fpage>271</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">14981520</pub-id>
              </element-citation>
            </ref>
            <ref id="spg3a.REF.zhao.2001.326">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zhao</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alvarado</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rainier</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lemons</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hedera</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weber</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tukel</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Apak</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heiman-Patterson</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ming</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bui</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fink</surname>
                    <given-names>JK</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Mutations in a novel GTPase cause autosomal dominant hereditary spastic paraplegia.</article-title>
                <source>Nat Genet</source>
                <volume>29</volume>
                <fpage>326</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">11685207</pub-id>
              </element-citation>
            </ref>
            <ref id="spg3a.REF.zhu.2003.49063">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zhu</surname>
                    <given-names>PP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patterson</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lavoie</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stadler</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shoeb</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patel</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blackstone</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Cellular localization, oligomerization, and membrane association of the hereditary spastic paraplegia 3A (SPG3A) protein atlastin.</article-title>
                <source>J Biol Chem</source>
                <volume>278</volume>
                <fpage>49063</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">14506257</pub-id>
              </element-citation>
            </ref>
            <ref id="spg3a.REF.zhu.2006.1343">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zhu</surname>
                    <given-names>PP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soderblom</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tao-Cheng</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stadler</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blackstone</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>SPG3A protein atlastin-1 is enriched in growth cones and promotes axon elongation during neuronal development.</article-title>
                <source>Hum Mol Genet</source>
                <year>2006</year>
                <volume>15</volume>
                <fpage>1343</fpage>
                <lpage>53</lpage>
                <pub-id pub-id-type="pmid">16537571</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="spg3a.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="spg3a.Author_Notes">
          <title>Author Notes</title>
          <p>Author&#x02019;s <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.mc.vanderbilt.edu/root/vumc.php?site=neurology&#x00026;doc=26232">Web page</ext-link></p>
        </sec>
        <sec id="spg3a.Acknowledgments">
          <title>Acknowledgments</title>
          <p>P. Hedera is supported by NIH (NINDS) grant K02NS057666</p>
        </sec>
        <sec id="spg3a.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>11 December 2014 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>9 February 2012 (cd) Revision: single-exon deletion in <italic toggle="yes">ATL1</italic> found to cause SPG3A [<xref ref-type="bibr" rid="spg3a.REF.sulek.2013.239">Sulek et al 2013</xref>]; HSN ID identified as allelic disorder</p>
            </list-item>
            <list-item>
              <p>21 September 2010 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>26 April 2010 (ph) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
